IL-1β induces thymic stromal lymphopoietin and an atopic dermatitis-like phenotype in reconstructed healthy human epidermis

J Pathol. 2017 Jun;242(2):234-245. doi: 10.1002/path.4887. Epub 2017 Apr 6.

Abstract

Atopic dermatitis (AD) is a common skin inflammatory disease characterized by the production of thymic stromal lymphopoietin (TSLP) and marked TH 2 polarization. Recent studies suggest that IL-1β contributes to the development of AD skin inflammation. Here, we have investigated the impact of IL-1β signalling on the epidermal homeostasis of both healthy subjects and AD patients [with functional filaggrin (FLG) alleles], with particular attention to TSLP production and keratinocyte differentiation. In healthy reconstructed human epidermis (RHE), IL-1β promoted (i) robust secretion of TSLP in an NF-κB-dependent manner and (ii) a significant decrease in the expression of filaggrin and other proteins of the epidermal differentiation complex. These effects were prevented by treatment of RHE with the anti-IL-1β mAb canakinumab and by the IL-1 receptor antagonist anakinra. Interestingly, RHE generated from AD donors behaved like that of healthy individuals and showed comparable responses to IL-1β signals. Collectively, our results suggest that IL-1β may be an early key mediator for the acquisition of an AD phenotype through induction of TSLP and alteration of the epidermal homeostasis. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Keywords: IL-1β; TSLP; atopic dermatitis; filaggrin; reconstructed human epidermis.

MeSH terms

  • Adult
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Cell Differentiation
  • Cytokines / genetics*
  • Cytokines / metabolism
  • Dermatitis, Atopic / drug therapy
  • Dermatitis, Atopic / genetics*
  • Dermatitis, Atopic / metabolism
  • Dermatitis, Atopic / pathology
  • Epidermis / metabolism
  • Epidermis / pathology
  • Female
  • Filaggrin Proteins
  • Homeostasis
  • Humans
  • Interleukin 1 Receptor Antagonist Protein / therapeutic use
  • Interleukin-1beta / genetics*
  • Interleukin-1beta / metabolism
  • Intermediate Filament Proteins / genetics
  • Intermediate Filament Proteins / metabolism
  • Male
  • Middle Aged
  • NF-kappa B / genetics
  • NF-kappa B / metabolism
  • Phenotype
  • Thymic Stromal Lymphopoietin
  • Young Adult

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Cytokines
  • FLG protein, human
  • Filaggrin Proteins
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-1beta
  • Intermediate Filament Proteins
  • NF-kappa B
  • canakinumab
  • Thymic Stromal Lymphopoietin